



- (51) International Patent Classification:
A61K 38/49 (2006.01)
- (21) International Application Number:
PCT/EP2012/065198
- (22) International Filing Date:
2 August 2012 (02.08.2012)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/515,506 5 August 2011 (05.08.2011) US
- (71) Applicant (for all designated States except US): **IFOM FONDAZIONE ISTITUTO FIRCA DI ONCOLOGIA MOLECOLARE** [IT/IT]; Via Adamello 16, I-20139 Milan (MI) (IT).
- (72) Inventors; and
- (73) Inventors/Applicants (for US only): **SIDENIUS, Nicolai** [DK/IT]; c/o Laboratorio Trasduzione del Segnale e Matrice Molecolare, IFOM Istituto FIRCA di Oncologia Molecolare, Campus IFOM-IEO, Via Adamello 16, I-20139 Milan (MI) (IT). **GANDHI, Sonu** [IN/IT]; c/o Laboratorio Trasduzione del Segnale e Matrice Molecolare, IFOM Istituto FIRCA di Oncologia Molecolare, Campus IFOM - IEO, Via Adamello 16, I-20139 Milan (MI) (IT).
- (74) Agents: **CAPASSO, Olga** et al.; De Simone & Partners SpA, Via Vincenzo Bellini 20, I-00198 Rome (IT).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report (Art. 21(3))

[Continued on next page]

(54) Title: CONSTITUTIVELY ACTIVE UPAR VARIANTS AND THEIR USE FOR THE GENERATION AND ISOLATION OF INHIBITORY ANTIBODIES




Fig. 5

(57) Abstract: The invention relates to variants of the urokinase plasminogen activator receptor (uPAR) that display remarkably increased vitronectin (VN) binding activity, possibly caused by a more efficient exposure of the VN binding site. The present invention also refers to antibodies raised against said uPAR variants, able to bind to the VN binding site of uPAR and then acting as inhibitors of uPAR functions, acting as functional antagonists of VN activated-uPAR functions. In the present invention such antibodies are monoclonal, polyclonal, synthetic or recombinant derivatives thereof, as synthetic antibodies (scFv) from phage-display libraries. Antibodies of the invention act as competitive antagonists.



— *with sequence listing part of description (Rule 5.2(a))*